44 2033180199

New pharmaceutical approaches to address the cognitive impairment associated with chronic obstructive pulmonary disease

Marcellino Monda, Rebecca Ross

With over 3.23 million fatalities per year, chronic obstructive pulmonary disease (COPD) is currently the third leading cause of mortality in the world and a significant global health burden. Globally, COPD costs about €82 billion annually and significantly increases morbidity and mortality. Importantly, managing COPD's comorbidities and acute exacerbations brought on by viruses and bacteria accounts for a large portion of the disease burden and health care use in this condition (AECOPD). Recent clinical investigations have demonstrated that cognitive dysfunction, including deficits in executive function, memory, and attention, is present in up to 60% of persons with COPD. This has an impact on crucial outcomes like quality of life, hospitalization, and survival.

Публикация рецензирования для ассоциаций, обществ и университетов pulsus-health-tech